Formulary guidance and transparency from P&T to point of care

Radar On Market Access: Health Care Deals May Slow in 2020, but Government Markets Remain Hot

Posted by Jane Anderson on Jan 9, 2020


The pace of health care mergers and acquisitions likely will cool slightly in 2020, some industry experts tell AIS Health. Still, insurers are likely to seek out companies with assets such as care management or information technology solutions, while provider consolidation will continue in certain markets, AIS Health reported.

"We expect that payer M&A will continue into 2020, with a bias toward vertical rather than horizontal deals," says Michael Abrams, managing partner of Numerof & Associates, Inc. "Payers will use such deals to expand into adjacent market spaces to differentiate their offerings as integrated platforms that can deliver superior value, customer experience and innovation."

Joe Paduda, a principal with Health Strategy Associates, says he expects less M&A generally in 2020, for several reasons. "There aren't as many assets to buy after the multiple deals done over the last few years; buyers are waiting to see results of the elections, which will drive their future strategy; and asset prices have edged even higher, making transactions more expensive and leaving less margin for error."

Dan Mendelson, the founder of consulting firm Avalere Health, says he still sees plenty of potential targets for horizontal mergers, along with more targets for vertical deals.

"Health plans are in a transformative phase right now. There are three major areas of focus: government markets, care management, and the information technology needed to support quality improvement and cost reduction," says Mendelson.

"In government markets, there are a range of quality assets that the larger plans could still acquire," he adds. "There are also some non-profits that could engage in collaboration with for-profit organizations to expand their scope and reach."

Medicare Advantage plans will be "a very strong target for M&A" in 2020, says Ashraf Shehata, KPMG's national sector leader for health care and life sciences.

Shehata says he also expects insurers to "amass capabilities around their PBMs." This, he says, could include bolstering their specialty pharmacy capabilities and building out technology.

Subscribe to the MMIT blog for more pharma, provider, and payer perspectives on key topics that affect the healthcare network.

Subscribe for Weekly Perspectives

Topics: Industry Trends, Provider, Payer